Why is Natco Pharma falling/rising?

As of 25-Sep, Natco Pharma Ltd. is experiencing a decline in its stock price, currently at 843.10, which reflects a decrease of 11.35 or 1.33%. The stock has been underperforming, having fallen consecutively for the last four days, resulting in a total return of -4.73% during this period. Additionally, it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. The stock's performance over the past week and month shows a decline of 4.66% and 3.63%, respectively, while its year-to-date performance is down by 39.21%. Despite a high management efficiency indicated by a return on equity (ROE) of 15.57% and a low debt-to-equity ratio, the stock's long-term growth prospects are overshadowed by its significant decline in value over the past year, where it has generated a return of -40.53%. In the broader market context, Natco Pharma's performance has been notably weaker compared to the benchmark, with the Sensex showing a decline of only 2.23% over the past week and a modest 0.58% over the past month. The stock's underperformance is further highlighted by its negative returns in both the short and long term, as it has lagged behind the BSE500 index. The falling investor participation, evidenced by a 47.68% drop in delivery volume, indicates a lack of confidence among investors. Although the company has high institutional holdings at 21.33%, which typically suggests a level of stability, the flat results reported in June and the overall below-par performance have contributed to the stock's current downward trajectory.